ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
AstraZeneca Plc (PK)

AstraZeneca Plc (PK) (AZNCF)

154.30
-0.0303
(-0.02%)
Closed July 20 4:00PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
154.30
Bid
154.20
Ask
157.85
Volume
1,261
154.30 Day's Range 154.30
118.16 52 Week Range 162.00
Market Cap
Previous Close
154.3303
Open
154.30
Last Trade
67
@
155.8799
Last Trade Time
Financial Volume
$ 194,572
VWAP
154.30
Average Volume (3m)
3,690
Shares Outstanding
1,550,189,338
Dividend Yield
1.88%
PE Ratio
31.55
Earnings Per Share (EPS)
3.84
Revenue
45.81B
Net Profit
5.96B

About AstraZeneca Plc (PK)

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Cambridge, Gbr
Founded
1970
AstraZeneca Plc (PK) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker AZNCF. The last closing price for AstraZeneca (PK) was $154.33. Over the last year, AstraZeneca (PK) shares have traded in a share price range of $ 118.16 to $ 162.00.

AstraZeneca (PK) currently has 1,550,189,338 shares outstanding. The market capitalization of AstraZeneca (PK) is $239.24 billion. AstraZeneca (PK) has a price to earnings ratio (PE ratio) of 31.55.

AZNCF Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.8399-1.17836632405156.1399160154.31063155.09252735CS
4-7.69-4.74720661769161.99161.99147.151096154.20953473CS
125.97514.02838633298148.3249162142.653690150.84680248CS
2619.8414.7553175666134.46162118.163320139.1526915CS
5219.2214.228605271135.08162118.163089135.44701264CS
15638.9733.7899939305115.33162104.53440127.54792718CS
26073.6491.296801388580.6616275.155628112.88249028CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SERVServe Robotics Inc
$ 7.51
(185.55%)
266.26M
AUGXAugmedix Inc
$ 2.27
(147.71%)
24.14M
XCURExicure Inc
$ 0.5351
(76.02%)
14.02M
PSNLPersonalis Inc
$ 3.83
(56.33%)
22.8M
MDBHMDB Capital Holdings LLC
$ 10.675
(37.21%)
126.45k
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
119.98M
HYZNHyzon Motors Inc
$ 0.149
(-47.54%)
23.37M
MEDSTRxADE Health Inc
$ 14.92
(-33.45%)
204.34k
SILOSilo Pharma Inc
$ 2.50
(-27.95%)
11.12M
KITTNauticus Robotics Inc
$ 0.0935
(-27.46%)
26.52M
SERVServe Robotics Inc
$ 7.51
(185.55%)
262.73M
NVDANVIDIA Corporation
$ 117.93
(-2.61%)
206.41M
SXTP60 Degrees Pharmaceuticals Inc
$ 0.2602
(5.77%)
202.14M
SQQQProShares UltraPro Short QQQ
$ 8.46
(2.79%)
184.21M
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
119.98M

AZNCF Discussion

View Posts
IHuser IHuser 2 months ago
imo. the whole world read my post and AZN jerked their "vaccine" off of the market....worldwide.


Let's go lawsuits..... * * ***...........let's go lawsuits clap clap clap clap clap!



AZN



IHuser
๐Ÿ‘๏ธ0
Monksdream Monksdream 3 months ago
AZN new 52 week high
๐Ÿ‘๏ธ0
IHuser IHuser 6 months ago
imo... dirty people play dirty little number tricks see link AZN

https://www.bitchute.com/video/RZXLkuLaJrnz/

IHuser
๐Ÿ‘๏ธ0
1jas 1jas 11 months ago
anyone here see where enzolytics announced yesterday that they have a cure called clone 3 that CURES hiv/aids.?
๐Ÿ‘๏ธ0
1jas 1jas 11 months ago
anyone here see where enzolytics announced yesterday that they have a cure called clone 3 that CURES hiv/aids.?
๐Ÿ‘๏ธ0
Stockexpertpro Stockexpertpro 1 year ago
lots of Deaths and Fatalities reported This could drop like a rock today heavy float lots of bagholders
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 1 year ago
Preprint https://www.biorxiv.org/content/10.1101/2023.06.20.545315v1
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 1 year ago
Next into the clinic should be this https://aacrjournals.org/cancerres/article/83/8_Supplement/LB085/725614/Abstract-LB085-Antitumor-activity-of-AZD0754-a

Also, a trial testing an CLDN18.2-targted version with the same dnTGFbRII armour is planned.

The first TCR-T therapy https://clinicaltrials.gov/ct2/show/NCT05877599 that is armoured as well http://www.neogene.com/staging/wp-content/uploads/2022/04/Keystone-2022-TGFBR2-KO-TP53-R175H-TCR-poster-final-edit.pdf

They have been working on additional edits https://jitc.bmj.com/content/10/Suppl_2/A253
๐Ÿ‘๏ธ0
BottomBounce BottomBounce 1 year ago
AstraZeneca PLC $AZN Total Debt (mrq) $32.47B
๐Ÿ‘๏ธ0
MI Dendream MI Dendream 1 year ago
Any idea why the delay for Ultomiris?
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 1 year ago
The company has inked a non-exclusive licensing deal with Revvity to use its Pin-point base editing platform in the development of new cell therapy treatments for cancer and other immune-mediated diseases. Pin-point uses a novel three-part design with an RNA aptamer guide, a modified Cas9 enzyme and a deaminase enzyme.

The platform is highly efficient and precise, allowing for multiplex editing with >75% editing in each target base. Also, has a strong safety profile with negligible off-target edits and no translocations. In addition, has no impact on cell health and allows for one-step complex engineering, which is simultaneous multiple knock-ins and knockouts (at least seven).
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 1 year ago
1st foray into CAR-T for $AZN; pres at AACR. GPC3 CAR w/ a dnTGF-B for HCC

Of 5 evaluable at DL1-2. 4/5 uPR (80% uORR). 5/5 tumor reduction; median -31%. Consistent AFP. Not squeaky clean but no DLTs

Promising start - green shoots showing in solid tumor cell therapy recently— Professor Oak (@Prof_Oak_) April 14, 2023
๐Ÿ‘๏ธ0
ernie44 ernie44 1 year ago
got the wrong stock..... wanted AEZS
๐Ÿ‘๏ธ0
DarthYoda DarthYoda 1 year ago
"INSIDE PFIZER AND ASTRAZENECA'S UKRAINIAN BIOLAB!":
https://www.bitchute.com/video/3JJO7BdvsDPz/
๐Ÿ‘๏ธ0
DarthYoda DarthYoda 1 year ago
New PCR Test warning...Sodium Azide..."REMEMBER THE PCR TESTS? WELL THE MSM HAVE CONFIRMED THAT THEY WERE LACED WITH POISONOUS CHEMICAL."

https://www.bitchute.com/video/0zl8fPbSao75/
๐Ÿ‘๏ธ0
DarthYoda DarthYoda 2 years ago
"THIS IS ABSOLUTELY BRILLIANTโ€ฆ STICKERS OF THE VACCINE INJURED ARE PLACE ON THE BBC HEADQUARTERS, A..":

https://www.bitchute.com/video/f2Y40NiPS6Kq/
๐Ÿ‘๏ธ0
DarthYoda DarthYoda 2 years ago
"GOVT SCANDALOUSLY MADE IT MANDATORY FOR CARE WORKERS TO BE VACCINATED OR SACKED - WITH NO RISK..."

https://www.bitchute.com/video/Jq0lLY1CXZhn/
๐Ÿ‘๏ธ0
BottomBounce BottomBounce 2 years ago
$AZN has $31.27 Billion DEBT
๐Ÿ‘๏ธ0
BottomBounce BottomBounce 2 years ago
$AZN Book Value only $11.35
๐Ÿ‘๏ธ0
barnyarddog barnyarddog 3 years ago
55.20, the FDA authorized the AstraZeneca drug called Evusheld for adults and children 12 and older whose immune systems haven't responded adequately to COVID-19 vaccines or have a history of severe allergic reactions to the shots. Regulators said the required two antibody injections may be effective at preventing COVID-19 infections for six months.

https://www.clickorlando.com/business/2021/12/08/us-oks-new-covid-19-antibody-drug-for-high-risk-patients/
๐Ÿ‘๏ธ0
BottomBounce BottomBounce 3 years ago
$AZN Pfizer And AstraZeneca Vaccines Were As Effective As Prior Infection, U.K. Study Finds
๐Ÿ‘๏ธ0
Tamtam Tamtam 3 years ago
IMFINZI and tremelimumab with chemotherapy improved progression-free survival by 28% and overall survival by 23% in 1st-line Stage IV non-small cell lung cancer vs. chemotherapy
๐Ÿ‘๏ธ0
Tamtam Tamtam 3 years ago
Well, well, well
https://m.republicworld.com/technology-news/social-media-news/facebook-suspends-russian-accounts-running-anti-vaccine-campaign-against-astrazeneca.html
๐Ÿ‘๏ธ0
Tamtam Tamtam 3 years ago
. U.K. Health secretary warns daily COVID-19 cases could reach 100,000
๐Ÿ‘๏ธ0
Tamtam Tamtam 3 years ago
. AstraZeneca COVID-19 vaccine is effective against variants identified in India
๐Ÿ‘๏ธ0
BottomBounce BottomBounce 3 years ago
$AZN EU Ditches AstraZeneca Vaccine. It's Pivoting to Pfizer. --
๐Ÿ‘๏ธ0
ernie44 ernie44 3 years ago
SEEMS LOW VOLUME ><((((((º>
๐Ÿ‘๏ธ0
Tamtam Tamtam 3 years ago
https://ih.advfn.com/stock-market/NYSE/astrazeneca-AZN/stock-news/84980530/farxiga-approved-in-the-us-for-the-treatment-of-ch
๐Ÿ‘๏ธ0
Tamtam Tamtam 3 years ago
FARXIGA Approved in the US for the Treatment of Chronic Kidney Disease
๐Ÿ‘๏ธ0
DCALongRun DCALongRun 3 years ago
Interesting graph on India.

๐Ÿ‘๏ธ0
BottomBounce BottomBounce 3 years ago
$AZN https://www.fool.com/investing/2021/04/22/pfizer-and-biontech-vaccine-sales-jump-14-billion/
๐Ÿ‘๏ธ0
ernie44 ernie44 3 years ago
my aptmt is april 8

dont want the AZN jab---its reported Sweden knows something
๐Ÿ‘๏ธ0
Tamtam Tamtam 3 years ago
โ€œ Emergentโ€™s plant implicated in vaccine mix-up had issues cited by FDA in 2020: APโ€ is this a joke?
๐Ÿ‘๏ธ0
ernie44 ernie44 3 years ago
still a problem---AZN vaccine has to be carefully used---and kept cool
๐Ÿ‘๏ธ0
IHuser IHuser 3 years ago
Reviews leave tbd ^ ^ ^ ^ ________________________AZN
๐Ÿ‘๏ธ0
I-Man I-Man 3 years ago

BELLUS Health Appoints William Mezzanotte, MD, MPH to its Board of Directors

LAVAL, Quebecโ€”March 24, 2021โ€” BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (โ€œBELLUS Healthโ€ or the โ€œCompanyโ€), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced the appointment of William Mezzanotte, MD, MPH to its Board of Directors. Dr. Mezzanotte brings decades of vast development and commercial experience to the Board, including the development and approval of 30 products across multiple therapeutic areas.

โ€œBill is a biopharmaceutical veteran with a proven drug development track record, including the approval of several drugs within the respiratory field,โ€ commented Dr. Francesco Bellini, Chairman of BELLUS Health. โ€œWe are pleased to welcome Bill to our Board of Directors, and we look forward to leveraging his extensive knowledge and guidance to help position BLU-5937 for clinical, regulatory and commercial success.โ€

Dr. Mezzanotte is currently the Head of Research and Development and Chief Medical Officer at CSL Behring, where he is responsible for developing and executing the Research & Development strategy and portfolio across four continents. Prior to CSL, he was Senior Vice President and Therapeutic Area Head, Respiratory for Boehringer Ingelheim. At Boehringer Ingelheim, he oversaw all Global Clinical Development, Medical Affairs, Marketing and Payer activities within the Respiratory portfolio, overseeing the launch of three respiratory products. Previously, Dr. Mezzanotte worked at AstraZeneca for over 15 years, assuming roles of increasing leadership and management responsibility in clinical research and development across multiple therapeutic areas. His last role there was Head of the Inflammation, Neuroscience and Respiratory Global Medicines Unit. Earlier in his career, Dr. Mezzanotte practiced Pulmonary and Critical Care Medicine and ran both a multispecialty sleep disorders center and a pulmonary diagnostics and interventional bronchoscopy laboratory. He received an undergraduate degree from Villanova University and obtained his MD at the University of Pennsylvania and MPH from Johns Hopkins University. Dr. Mezzanotte is board certified in internal medicine, pulmonary medicine, critical care medicine and sleep medicine.

โ€œI am excited to join BELLUSโ€™ Board and contribute to the development of the Companyโ€™s promising lead candidate, BLU-5937,โ€ said Dr. Mezzanotte. โ€œPatients with refractory chronic cough have no FDA-approved treatments to help alleviate their symptoms. As a highly selective and differentiated P2X3 antagonist, BLU-5937 has the potential to offer meaningful improvement for these patients. I look forward to working with the BELLUS management team and other members of the Board to potentially bring this exciting therapy to the millions of patients that suffer from refractory chronic cough, as well as other hypersensitization-related disorders.โ€

About BELLUS Health (www.bellushealth.com)

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of refractory chronic cough and chronic pruritus associated with atopic dermatitis.

Refractory chronic cough is a cough lasting more than 8 weeks despite appropriate treatment for underlying condition(s). It is estimated that there are approximately 9 million patients in the United States suffering from refractory chronic cough. Refractory chronic cough is associated with significant adverse physical, social, and psychosocial effects on health and quality of life. Currently, there is no specific therapy approved for refractory chronic cough and current treatment options are limited.
๐Ÿ‘๏ธ0
dsscam dsscam 3 years ago
$AZN- true bozos from top to bottom https://www.cnbc.com/2021/03/11/denmark-suspends-use-of-astrazeneca-vaccine-over-reports-of-blood-clots.html
๐Ÿ‘๏ธ0
Tamtam Tamtam 3 years ago
. AstraZenecaโ€™s COVID-19 shot is said to work against Brazil variant: Reuters
๐Ÿ‘๏ธ0
Tamtam Tamtam 3 years ago
AstraZenecaโ€™s COVID-19 shots reach Ghana as UN-backed COVAX initiates deliveries

https://ih.advfn.com/stock-market/NYSE/astrazeneca-AZN/stock-news/84421958/astrazeneca-s-covid-19-shots-reach-ghana-as-un-ba
๐Ÿ‘๏ธ0
Tamtam Tamtam 3 years ago
WHO approves AstraZeneca/Oxford COVID-19 vaccine for emergency use

https://www.reuters.com/article/us-health-coronavirus-who-astrazeneca-idUSKBN2AF1KC
๐Ÿ‘๏ธ0
Tamtam Tamtam 3 years ago
AstraZeneca Wins WHO Emergency Listing For COVID-19 Vaccine; Street Sees 31% Upside
https://ih.advfn.com/stock-market/NYSE/astrazeneca-AZN/stock-news/84342162/astrazeneca-wins-who-emergency-listing-for-covid-1
๐Ÿ‘๏ธ0
Tamtam Tamtam 4 years ago
Serum Institute expects WHO emergency approval for AstraZeneca Covid-19 vaccine Novavax soon

https://www.deccanherald.com/national/serum-institute-expects-who-emergency-approval-for-astrazeneca-covid-19-vaccine-novavax-soon-938986.html
๐Ÿ‘๏ธ0
Tamtam Tamtam 4 years ago
AstraZeneca has applied for authorization for its Covid-19 vaccine in Europe and the EU pharmaceutical regulator said Tuesday it could give the go-ahead as early as Jan. 29. That´s when the European Medicines Agency´s scientific committee will meet to review analysis of the vaccine´s trial data and, if it recommends authorization, the European Commission could formally authorize AstraZeneca´s vaccine within a few days. If AstraZeneca´s Covid-19 vaccine, which was developed with Oxford University, were authorized for emergency use, it would add at least 300 million doses to the continent´s attempts to limit its deadly winter surge in Covid-19 infections. The EU has preordered 300 million doses with an option for another 100 million, and AstraZeneca has said it will manufacture up to three billion doses of its vaccine this year, which will be crucial in the effort to get doses administered in poorer countries.
๐Ÿ‘๏ธ0
Tamtam Tamtam 4 years ago
FARXIGA Granted Priority Review in the US for the Treatment of Patients With Chronic Kidney Disease

https://ih.advfn.com/stock-market/NYSE/astrazeneca-AZN/stock-news/84033951/farxiga-granted-priority-review-in-the-us-for-the
๐Ÿ‘๏ธ0
BottomBounce BottomBounce 4 years ago
$AZN https://www.calcalistech.com/ctech/articles/0,7340,L-3884172,00.html
๐Ÿ‘๏ธ0
north40000 north40000 4 years ago
MHRA approves use of AZN/Oxford vaccine for use in U.K.
๐Ÿ‘๏ธ0
Tamtam Tamtam 4 years ago
AstraZenecaโ€™s vaccine formula is 100% effective against severe COVID-19.
https://www.timesofisrael.com/astrazeneca-winning-vaccine-formula-is-100-effective-against-severe-covid-19/
๐Ÿ‘๏ธ0
Esa Esa 4 years ago
https://www.theguardian.com/world/2020/dec/25/uk-scientists-trial-drug-to-prevent-coronavirus-infection-leading-to-disease

https://news.sky.com/story/covid-19-trials-begin-on-antibody-treatment-that-could-prevent-illness-in-those-recently-exposed-12172623
๐Ÿ‘๏ธ0
BottomBounce BottomBounce 4 years ago
$AZN Why AstraZeneca's and Sanofi's Bad News Could Be Great News for Pfizer and Moderna

https://fool.com/investing/2020/12/16/why-astrazenecas-and-sanofis-bad-news-could-be-gre/
๐Ÿ‘๏ธ0
speakcheesy speakcheesy 4 years ago
Selling pressure from the arb's driving the stock lower
AstraZeneca $AZN and Alexion $ALXN Factsheet for traders and investors looking to trade the merger arbitrage spread
https://mergerarbitragelimited.com/astrazeneca-azn-and-alexion-alxn-merger/
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock